FDA Comes to China II
Yesterday, I posed the question whether the U.S. FDA had the resources to adequately conduct inspections over here in China. Here is one opinion, and it’s a negative one:
The FDA is overburdened and underfunded; it has trouble policing domestic pharmaceutical companies adequately. So how does the government and pharmaceutical companies think they can adequately monitor ingredients made in China?
